Gdc 0941

Manufactured by Chemietek

Sourced in United States

GDC-0941 is a laboratory instrument designed for research purposes. It is a small-molecule inhibitor that targets the phosphoinositide 3-kinase (PI3K) enzyme. The core function of GDC-0941 is to serve as a research tool for investigating the role of the PI3K signaling pathway in various biological processes and disease models.

Automatically generated - may contain errors

Lab products found in correlation

Abt 263, by Active Motif (1 mentions) Abt 199, by Active Motif (1 mentions) Nvp bez235, by Novartis (1 mentions) Romidepsin, by Selleck Chemicals (1 mentions) Ulixertinib, by Selleck Chemicals (1 mentions) Nvp bez235, by Chemietek (1 mentions) Azd8055, by Chemietek (1 mentions) Otx015, by Cayman Chemical (1 mentions) Q vd oph, by Apexbio (1 mentions) Rapamycin, by R&D Systems (1 mentions) Pd0325901, by Chemietek (1 mentions) Mk 2206, by Chemietek (1 mentions) Q vd oph, by R&D Systems (1 mentions) Vx 11e, by Chemietek (1 mentions)

3 protocols using gdc 0941

Characterization of KRAS/EGFR Mutant NSCLC Cell Lines

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Human KRAS mutant and EGFR mutant NSLCLC cell lines were obtained from the Center for Molecular Therapeutics at the MGH Cancer Center which performs routine SNP and STR authentication (21 (link)); cell lines were passaged for less than 6 months following receipt. A427-R and DV-90-R resistant cell lines were generated by exposing parental cell lines to 1 μM AZD6244/GDC-0941 for three days followed by drug washout for 3 days. Cells were treated for 5-10 cycles, followed by maintenance in the continuous presence of drug. The N1, N2 (treatment naïve) and R1, R2, R3 (AZD6244/BEZ235 resistant) lines are tumor-derived cell lines from Kras p53^L/L mice. For cell culture studies, AZD6244 (Otava), GDC-0941 (Chemietek), ABT-263 (Active Biochem), ABT-199 (Active Biochem), NVP-BEZ235 (kindly provided by Novartis) were dissolved in DMSO to a final concentration of 10 mmol/l and stored at −20°C. Antibodies utilized for western blotting are listed in Supplementary Materials and Methods.

Hata A.N., Yeo A., Faber A.C., Lifshits E., Chen Z., Cheng K.A., Walton Z., Sarosiek K.A., Letai A., Heist R.S., Mino-Kenudson M., Wong K.K, & Engelman J.A. (2014). Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS mutant lung cancers. Cancer research, 74(11), 3146-3156.

+ Open protocol

+ Expand

Combinatorial Inhibitor Treatment Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

The HDI romidepsin (Cat #S3020) and the ERK inhibitor ulixertinib (Cat #S7854) were purchased from Selleck Chemicals (Houston, TX, USA). The PI3K inhibitor GDC-0941 (Cat #CT-G0941) and mTOR inhibitors AZD-8055 (Cat #CT-A8055) and NVP-BEZ235 (Cat #CT-BEZ) were from ChemieTek (Indianapolis, IN, USA). The mTOR inhibitor rapamycin (Cat #1292) was obtained from Tocris/R&D Systems (Minneapolis, MN, USA). The BRD inhibitor OTX-015 (Cat #15947) was purchased from Cayman Chemicals (Ann Arbor, MI, USA). The pan-caspase inhibitor Q-VD-OPh (Cat #A1901) was obtained from ApexBio Technology (Houston, TX, USA).

Patel R.P., Thomas J.R., Curt K.M., Fitzsimmons C.M., Batista P.J., Bates S.E., Gottesman M.M, & Robey R.W. (2021). Dual Inhibition of Histone Deacetylases and the Mechanistic Target of Rapamycin Promotes Apoptosis in Cell Line Models of Uveal Melanoma. Investigative Ophthalmology & Visual Science, 62(12), 16.

+ Open protocol

+ Expand

Inhibitors of Cell Signaling Pathways

Check if the same lab product or an alternative is used in the 5 most similar protocols

Romidepsin was obtained from the Developmental Therapeutics Program of the National Cancer Institute (Bethesda MD). The MEK inhibitor PD-0325901, the AKT inhibitor MK-2206, the ERK inhibitor Vx-11e and the PI3K inhibitor GDC-0941 were purchased from ChemieTek (Indianapolis, IN). Q-VD-OPh was from R&D Systems (Minneapolis, MN). The dual pathway inhibitor, D-87503, was synthesized in-house by the Chemical Biology Laboratory, Center for Cancer Research (Frederick, MD).

Bahr J.C., Robey R.W., Luchenko V., Basseville A., Chakraborty A.R., Kozlowski H., Pauly G.T., Patel P., Schneider J.P., Gottesman M.M, & Bates S.E. (2016). Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras. Oncotarget, 7(43), 69804-69815.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!